Report overview
Gene therapy (gene therapy) refers to the introduction of foreign normal genes into target cells to correct or compensate for diseases caused by defects and abnormal genes in order to achieve therapeutic purposes. It also includes the application of technology such as transgenes, that is, inserting foreign genes into appropriate recipient cells of patients through gene transfer technology, so that the products made by foreign genes can treat certain diseases. Broadly speaking, gene therapy can also include measures and new technologies taken from the DNA level to treat certain diseases. Cell therapy is a brand-new drug development model. In this type of therapy, immune cell therapy has proved to have the most potential. Now researchers have demonstrated its clinical benefits in the treatment of cancer and infectious diseases, and these There are many different characteristics between therapy and traditional therapy, including its ability to expand and contract as needed, and to adjust the therapeutic effect of the body within a few months or years after a single application; due to basic immunology, gene function, gene editing With the continuous application and progress of synthetic biology, the complexity of immune cell therapy has been greatly expanded, which can improve the effectiveness and safety of immune cell therapy, and also increase its potential for treating diseases.
This report aims to provide a comprehensive presentation of the global market for Cell and Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Gene Therapy. This report contains market size and forecasts of Cell and Gene Therapy in global, including the following market information:
Global Cell and Gene Therapy Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
The global Cell and Gene Therapy market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Rare Diseases Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Cell and Gene Therapy include Amgen Inc., bluebird bio, Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cells Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG and Orchard Therapeutics plc., etc. in 2023, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cell and Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cell and Gene Therapy Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Cell and Gene Therapy Market Segment Percentages, by Type, 2023 (%)
Rare Diseases
Oncology
Hematology
Cardiovascular
Ophthalmology
Neurology
Other Therapeutic Classes
Global Cell and Gene Therapy Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Cell and Gene Therapy Market Segment Percentages, by Application, 2023 (%)
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Contract Research Organizations (CROs)
Hospital
Others
Global Cell and Gene Therapy Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Cell and Gene Therapy Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cell and Gene Therapy revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Cell and Gene Therapy revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen Inc.
bluebird bio, Inc.
Dendreon Pharmaceuticals LLC.
Fibrocell Science, Inc.
Human Stem Cells Institute
Kite Pharma, Inc.
Kolon TissueGene, Inc.
Novartis AG
Orchard Therapeutics plc.
Organogenesis Holdings Inc.
Pfizer, Inc.
RENOVA THERAPEUTICS
Shanghai Sunway Biotech Co., Ltd.,
Sibiono GeneTech Co. Ltd.,
Spark Therapeutics, Inc.
Vericel Corporation
ViroMed Co., Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cell and Gene Therapy, market overview.
Chapter 2: Global Cell and Gene Therapy market size in revenue.
Chapter 3: Detailed analysis of Cell and Gene Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cell and Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
